Biotech Values

[DewDiligence]

ENTA IPO’s at $14/share:

http://finance.yahoo.com/news/enanta-pharmaceuticals-announces-pricing-initial-215500967.html

Enanta’s claim to fame is ABT-450, the HCV protease inhibitor that ABBV licensed in 2006 and is testing in various all-oral combinations. In the original deal, ENTA had an option to own 40% of the commercial rights to ABT-450 in the US (#msg-15492225); I do not know if this option has been exercised.

ENTA also has a purported HCV collaboration with NVS for the NS5A inhibitor, EDP-239 (#msg-72334186); I use the word purported because NVS never talks about this compound (or about anything to do with HCV for that matter).